Clinical Research Directory
Browse clinical research sites, groups, and studies.
Low-Dose Spironolactone in Hemodialysis Patients With Resistant Hypertension
Sponsor: Universitas Sebelas Maret
Summary
Many patients on hemodialysis have high blood pressure that does not respond to three or more drugs (resistant hypertension). This pilot study gave a low dose of spironolactone (12.5 mg once daily) for 6 weeks to adults on hemodialysis with resistant hypertension. The study measured changes in blood pressure, heart rate variability, markers of inflammation (interleukin-6 and high-sensitivity C-reactive protein), a marker of cardiac stress (NT-proBNP), and serum potassium.
Official title: Low-Dose Spironolactone and Changes in Blood Pressure, Heart Rate Variability, and Inflammatory and Cardiac Biomarkers in Hemodialysis Patients With Resistant Hypertension: A Single-Arm Pre-Post Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2024-08-20
Completion Date
2024-10-31
Last Updated
2026-10-22
Healthy Volunteers
No
Interventions
Spironolactone
Spironolactone 12.5 mg taken orally once daily for 6 weeks.
Locations (1)
Dr. Moewardi General Hospital
Surakarta, Central Java, Indonesia